Recent developments in the pharmacological treatment of Crohn’s disease

Bibliography

• CROHN BB, GINZBERG L, OPPENHEIMER GD: Regional enteritis: a pathological and clinical entity. JAMA (1932) 99:1323.
   Google Scholar
• BEST WR, BECKTAL JM, SINGLETON JVV, KERN F: Development of a Crohn's disease activity index: National cooperative Crohn's disease study. Gastroenterology (1976) 70:439–444.
   PubMed Web of Science ®Google Scholar
• HARVEY RE BRADSHAW JM: A simple index of Crohn's disease activity. Lancet (1980) 1:514–515.
   PubMed Web of Science ®Google Scholar
• GUYATT G, MITCHELL A, IRVINE EJ et al.: A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology (1989) 96:804–810.
   PubMed Web of Science ®Google Scholar
• VAN DULLEMEN HM, VAN DEVENTER SJ, HOMMES DW et al.: Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology (1995) 109:129–135.
   PubMed Web of Science ®Google Scholar
• TARGAN SR, HANAUER SB, VAN DEVENTER SJ et al.: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. New Engl. J. Med. (1997) 337:1029–1035.
   Google Scholar
• PRESENT DH, RUTGEERTS P, TARGAN S et al: Infliximab for the treatment of fistulas in patients with Crohn's disease. New Engl. J. Med. (1999) 340:1398–1405.
   PubMed Web of Science ®Google Scholar
• RUTGEERTS P, D'HAENS G, TARGAN S et al: Efficacy and safety of treatment with with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology (1999) 117:761–769.
   PubMed Web of Science ®Google Scholar
• HANAUER SB, FEAGAN BG, LICHTENSTEIN GR et al.: Maintenance infliximab for Crohn's disease: the ACCENT 1 randomized trial. Lancet (2002) 359:1541–1549.
   PubMed Web of Science ®Google Scholar
• SANDBORN WJ, FEAGAN BG, HANAUER SB et al.: An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology (2001) 120:1330–1338.
   PubMed Web of Science ®Google Scholar
• FEAGAN BG, SANDBORN WJ, BAKER JP et al.: A randomized, double-blind, placebo, controlled multi-center trial of the engineered human antibody to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn's disease. Proceedings of the Digestive Disease Week, San Diego, USA (2000):A655.
   Google Scholar
• SANDBORN WJ, FEAGAN B, RADFORD-SMITH G, KOVACS A, ENNS R, PATEL J: A randomized, placebo-controlled trial of CDP571, a humanized monoclonal antibody to TNF-a, in patients with moderate to severe Crohn's disease. Proceedings of the Digestive Disease Week, Orlando, USA (2003):A469.
   Google Scholar
• D'HAENS G, SWIJSEN C, NORMAN M et al.: Etanercept (TNF receptor fusion protein, Enbrel) is effective and well tolerated in active refractory Crohn's disease: results of a single center pilot trial. Proceedings of the Digestive Disease Week, Atlanta, USA (2001):A656.
   Google Scholar
• SANDBORN WJ, HANAUER SB, KATZ S et al.: Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology (2001) 121:1088–1094.
   PubMed Web of Science ®Google Scholar
• ••This study showed that etanercept at 25mg twice-weekly had no benefit in CD.
   Google Scholar
• RUTGEERTS P, LEMMENS L, GERT VAN ASSCHE et al.: Recombinant soluble p55 TNF receptor induces remission, is non immunogenic and well tolerated in active Crohn's disease: results of a randomized pilot trial. Proceedings of the Digestive Disease Week, Atlanta, USA (2001):A2304.
   Google Scholar
• RUTGEERTS P, LEMMENS L, VAN ASSCHE G, NOMAN M, BORGHINI-FUHRER I, GOEDKOOP R: Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumor necrosis factor receptor): results of a randomized, open-label, pilot study. Ailment. Pharmacol Thec (2003) 17:185–192.
   PubMed Web of Science ®Google Scholar
• •A pilot study that has shown treatment benefit of onercept in CD.
   Google Scholar
• MacHOLD KP, SMOLEN JS: Adalimumab - a new TNF-alpha antibody for treatment of inflammatory joint disease. Expert Opin. Investig. Drugs (2003) 3(2):351–360.
   Web of Science ®Google Scholar
• SCHREIBER S, RUTGEERTS P, FED ORAK R, KHALIQ-KAREEMI M, KAMM MA, PATEL J: CDP 870, a humanized anti-TNF antibody fragment, induces clinical response with remission in patients with active Crohn's disease. Proceedings of the Digestive Disease Week, Orlando, USA (2003):A468.
   Google Scholar
• SCHREIBER S, WINTER T, INNES A, PATEL J: Safety of CDP870, a pegylated humanized anti-TNF antibody fragment, in Crohn's disease. Proceedings of the American College of Gastroenterology Annual Meeting, Baltimore, USA (2003):A300.
   Google Scholar
• SCHREIBER S, RUTGEERTS P, INNES A, PATEL J: CDP870, a pegylated humanized anti-TNF antibody fragment, offers particular benefit to Crohn's disease patients with elevated C-reactive protein. Proceedings of the American College of Gastroenterology Annual Meeting. Baltimore, USA (2003):A299.
   Google Scholar
• •Has shown that CD patients with elevated levels of CRP may be a different subgroup in terms of treatment response to anti-TNF therapy.
   Google Scholar
• SANDS BE, POD OLSKY DK: New life in a sleeper: Thalidomide and Crohn's disease. Gastroenterology (1999) 117:1485–1488.
   PubMed Web of Science ®Google Scholar
• EHRENPREIS ED, KANE SV, COHEN LB et al.: Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology (1999) 117:1271–1277.
   PubMed Web of Science ®Google Scholar
• VASILIAUSKAS EA, KAM LY, ABREU-MARTIN MT et al.: An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology (1999) 117:1278–1287.
   PubMed Web of Science ®Google Scholar
• FACCHINI S, CANDUSSO M, MARTELOSSI S et al.: Efficacy of long-term treatment with thalidomide in children and young adults with Crohn disease: preliminary results. J. Pediati: Gastroenterol Nutr. (2001) 32:178–181.
   PubMed Web of Science ®Google Scholar
• BAUDITZ J, WEDEL S, LOCHS H: Thalidomide reduces tumor necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. Gut (2002) 50(2):196–200.
   Google Scholar
• OLIVER SJ, FREEMAN SL, CORRAL LG, OCAMPO CJ, KAPLAN G: Thalidomide analogue CC1069 inhibits development of rat adjuvant arthritis. Clin. Exp. Immunol. (1999) 118(2):315–321.
   PubMed Web of Science ®Google Scholar
• MARRIOT JB, WESTBY M, COOKSON S et al.: CC-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production. I Immunol. (1998) 161(8):4236–4243.
   PubMed Web of Science ®Google Scholar
• •Paved the way for use of thalidomide analogues that have fewer side effects than thalidomide in inflammatory diseases like arthritis and CD.
   Google Scholar
• BARLOGIE B: Pilot Phase I/II trial of CCHH-1088 versus placebo in Crohn's disease. Proceedings of the SMA Anti-Arthritic Agents Meeting, London, UK (2003).
   Google Scholar
• HOMMES D, VAN DER BLINK B, PLASSE T et al.: Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology (2002) 122(1):7–14.
   Google Scholar
• WOLLHEIM FA: TNF inhibition as therapy for rheumatoid arthritis. Expert Opin. Investig. Drugs (2002) 11(7):947–953.
   PubMed Web of Science ®Google Scholar
• BAUDITZ J, HAEMLING J, ORTNER M, LOCHS H, RAEDLER A, SCHREIBER S: Treatment with tumor necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease. Gut (1997) 40(4):470–474.
   PubMed Web of Science ®Google Scholar
• CONWAY JG, ANDREWS RC, BEAUDET B et al: Inhibition of tumor necrosis factor-alpha production and arthritis in the rat by GW3333, a dual inhibitor of TNF-alpha converting enzyme and matrix metalloproteinases. .1. Pharmacol. Exp. Ther. (2001) 298:900–908.
   PubMed Web of Science ®Google Scholar
• Preclinical data on doramapimod. Proceedings of the Drug Discovery Technology meeting, Boston, USA (2002).
   Google Scholar
• DUCHMANN R, SCHMITT E, KNOLLE P et al.: Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Ear: .1. Immunol. (1996) 26:934–938.
   Google Scholar
• KUHN R, LOHLER J, RENNICK D et al: Interleukin-10-deficient mice develop chronic enterocolitis. Cell (1993) 75:263–274.
   PubMed Web of Science ®Google Scholar
• VAN DEVENTER SJ, ELSON CO, FEDORAK RN: Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology (1997) 113:383–389.
   PubMed Web of Science ®Google Scholar
• FEDORAK RN, GANGL A, ELSON CO et al.: Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology (2000) 119:1473–1482.
   Google Scholar
• •This study failed to show efficacy of rhIL-10 in treatment of mild-to-moderately active CD.
   Google Scholar
• SCHREIBER S, FEDORAK RN, NIELSEN OH et al: Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology (2000) 119:1461–1472.
   PubMed Web of Science ®Google Scholar
• LINDSAY JO, CIESIELSKI CJ, SCHEININ T, BRENNAN FM, HODGSON HJ: Local delivery of adenoviral vectors encoding murine interleukin 10 induces colonic interleukin 10 production and is therapeutic for murine colitis. Gut (2003) 52:363–369.
   PubMed Web of Science ®Google Scholar
• ••This novel approach, by using adenoviralvectors to induce murine colonic IL-10 production and thereby restore mucosal immune homeostasis, is ground breaking and bodes well for future human studies.
   Google Scholar
• VAN MONTFRANS C, RODRIGUES PENA MS, PRONK I, TEN KATE FJW, TE VELDE AA, VAN DEVENTER SJH: Prevention of colitis by interleukin 10-transducedT lymphocytes in the SCID mice transfer model. Gastroenterology (2002) 123: 1865-1876.
   Google Scholar
• GREENWOOD-VAN MEERVELD B, VENKOVA K, KEITH JC Jr: Recombinant human interleukin-11 restores smooth muscle function in the jejunum and colon of human leukocyte antigen-B27 rats with intestinal inflammation. Pharmacol. Exp. The]: (2001) 299:58–66.
   Google Scholar
• KEITH JC Jr, ALBERT L, SONIS ST et al.: IL-11, a pleiotropic cytokine: exciting new effects of IL-11 on gastrointestinal mucosal biology. Stem Cells (1994) (Suppl. 1):79–89.
   Google Scholar
• PETERSON RL, WANG L, ALBERT L et al.: Molecular effects of recombinant human interleukin-11 in the HLA-B27 rat model of inflammatory bowel disease. Lab. Invest. (1998) 78:1503–1512.
   PubMed Web of Science ®Google Scholar
• QIU BS, PFEIFFER CJ, KEITH JC Jr: Protection by recombinant human interleukin-11 against experimental TNB-induced colitis in rats. Dig. Dis. Sci. (1996) 41:1625–1630.
   PubMed Web of Science ®Google Scholar
• SCHWERTSCHLAG US, TREPICCHIO WL, DYKSTRA KH et al.: Hematopoietic, immunomodulatory and epithelial effects of interleukin-11. Leukemia (1999) 13:1307–1315.
   PubMed Web of Science ®Google Scholar
• SANDS BE, BANKS, SNINSKY CA et al:Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology (1999) 117:58–64.
   PubMed Web of Science ®Google Scholar
• J-695, also known as ABT-874 drug report. The Investigational Drugs Database. August 2003.
   Google Scholar
• RANDLE JCR, HARDING MW, KU G, SCHONHARTING M, KURRLE R: ICE/Caspase-1 inhibitors as novel anti-inflammatory drugs. Expert Opin. Investig. Drugs (2001) 10:1207–1209.
   PubMed Web of Science ®Google Scholar
• LOHER F, BAUER C, SCHMALL K et al.:The ICE inhibitor, pralnacasan, reduces DSS-induced murine colitis and Thl-cell activation. Proceedings of the VIth International Symposium on Inflammatory Bowel Diseases, Istanbul ( 2001).
   Google Scholar
• •Animal studies of this agent have shown that it can reduce colonic inflammation and TH1 cell activation. Human studies are awaited as CD is a predominantly TH1 disease and this drug should prove beneficial.
   Google Scholar
• LOVELL DJ, BOWYER SL: Treatment of neonatal onset multisystem inflammatory disease (NOMID) with interleukin-1 receptor antagonists (Anakinra). Proceedings of the American College of Rheumatology Meeting, Orlando, USA (2003):A1313.
   Google Scholar
• YACYSHYN BR, BOWEN- YACYSHYN MB, JEWELL L et al: A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology (1998) 114:1133–1142.
   PubMed Web of Science ®Google Scholar
• SCHREIBER S, NIKOLAUS S, MALCHOW H et al.: Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology (2001) 120:1339–1346.
   PubMed Web of Science ®Google Scholar
• YACYSHYN BR, CHEY W, GOFF J et al.: Double-blinded, randomized, placebo-controlled trial of the remission inducing and steroid sparing properties of two schedules of ISIS 2302 (ICAM-1 antisense) in active, steroid-dependent Crohn's disease. Proceedings of the Digestive Disease Week, San Diego, USA (2000):A570.
   Google Scholar
• MINER PB, BANE BL, SADIQ SA, BRADLEY JD, WEDEL M: Antisense inhibitor of ICAM-1 given as enema improves symptomatic pouchitis. Proceedings of the Digestive Disease Week, (2003) Orlando, USA (2003) (Abstract T1395)
   Google Scholar
• PICARELLA D, HURLBUT P, ROTTMAN J et al.: Monoclonal antibodies specific for beta 7 integrin and mucosal cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of SCID mice reconstituted with CD45RBhigh CD4+ T cells. J. Immunol (1997) 158:2099–2106.
   PubMed Web of Science ®Google Scholar
• PODOLSKY DK, LOBB R, KING N et al.: Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody. J. Clin. Invest. (1993) 92:372–380.
   PubMed Web of Science ®Google Scholar
• FEAGAN B, GREENBERG G, WILD G et al.: A randomized controlled trial of a humanized antibody in ulcerative colitis. Proceedings of the American College of Gastroenterology Annual Meeting, Baltimore, USA (2003) A9.
   Google Scholar
• GORDON FH, LAI CWY, HAMILTON MI et al.: A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha-4 integrin in active Crohn's disease. Gastroenterology (2001) 121:268–274.
   PubMed Web of Science ®Google Scholar
• GHOSH S, GOLDIN E, GORDON FH et al.: Natalizumab for active Crohn's disease. New Engl. I Med. (2003) 348:24–32.
   PubMed Web of Science ®Google Scholar
• ••CD patients showed both response andremission of their disease at week 6 when they received two infusions of the drug. Quality-of-life scales also showed an improvement.
   Google Scholar
• SANDBORN W, COLOMBEL JF, ENNS R et al.: Results from a Phase III study on the evaluation of natalizumab in active Crohn's disease therapy-1 (ENACT-1). Proceedings of the American College of Gastroenterology Annual Meeting, Baltimore, USA (2003) (Abstract 55A).
   Google Scholar
• KORZENIK JR, DIECKGRAEFE BK: Is Crohn's disease an immunodeficiency? A hypothesis suggesting possible early events in the pathogenesis of' Crohn's disease. Dig. Dis. Sci. (2000) 45:1121–1129.
   PubMed Web of Science ®Google Scholar
• KORZENIK JR, DIECKGRAEFE BK: Immunostimulation in Crohn's disease: results of a pilot study of G-CSF (rhu G-CSF) in mucosal and fistulizing Crohn's disease. Proceedings of the Digestive Disease Week meeting, San Diego, USA (2000):A874–A875.
   Google Scholar
• DEJACO C, GASCHE C, POETZI R et al.: Safety and efficacy of granulocyte colony stimulating factor (G-CSF) for treatment of severe endoscopic postoperative recurrence in Crohn's disease. Proceedings of the Digestive Disease Week, San Diego, USA (2000):A566.
   Google Scholar
• KORZENIK JR, DIECKGRAEFE BK: Immune stimulation in Crohn's disease: Safety and efficacy of rhuGM-CSF for the treatment of active Crohn's disease. Proceedings of the Digestive Disease Week, Atlanta, USA (2001):A277–A278.
   Google Scholar
• KORZENIK J, DIECKGRAEFE B, VALENTINE JF: Sargramostim (Leukine) induces response and remission in moderately to severely active Crohn's disease: results from the first randomized, double-blind, placebo-controlled trial. Proceedings of the Annual Meeting of the American College of Gastroenterology„ Baltimore, USA (2003) 49A.
   Google Scholar
• •This study tested the hypothesis that impaired neutrophil and/or monocyte function is the underlying pathogenic defect in some CD patients rather than excessive T-cell response by treating patients with GM-CSF versus placebo.
   Google Scholar
• TONTONOZ P, HU E, SPIEGELMAN BM: Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell (1994) 79:1147–1156.
   PubMed Web of Science ®Google Scholar
• TONTONOZ P, HU E, GRAVES RA, BUDAVARI Al, SPIEGELMAN BM: mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. (1994) 8:1224–1234.
   PubMed Web of Science ®Google Scholar
• CHAWLA A, SCHWARZ EJ, DIMACULANGAN DD, LAZAR MA: Perwdsome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology (1994) 135:798–800.
   PubMed Web of Science ®Google Scholar
• FAJAS L, AUBOEUF D, RASPE E et al:The organization, promoter analysis, and expression of the human PPARgamma gene. Biol. Chem. (1997) 272:18779–18789.
   Web of Science ®Google Scholar
• SU CG, WEN X, BAILEY ST et al.: A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. I Clin. Invest. (1999) 104:383–389.
   PubMed Web of Science ®Google Scholar
• KATAYAMA K, WADA K, NAKAJIMA A et al: A novel PPAR gamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model. Gastroenterology (2003) 124:1315–1324.
   PubMed Web of Science ®Google Scholar
• TANAKA T, KOHNO H, YOSHITANI S et al.: Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res. (2001) 61:2424–2428.
   PubMed Web of Science ®Google Scholar
• SAUBERMANN LJ, NAKAJIMA A, WADA K et al.: Perwdsome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis. Inflamm. Bowel Dis. (2002) 8:330–339.
   PubMed Web of Science ®Google Scholar
• DESREUMAUX P, DUBUQUOY L, NUTTEN S et al.: Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies. J. Exp. Med. (2001) 193:827–838.
   Google Scholar
• •Raised the possibility that a PPAR-y heterodimer may be of therapeutic benefit in colonic inflammation.
   Google Scholar
• NAKAJIMA A,WADA K, MIKI H et al: Endogenous PPAR gamma mediates anti-inflammatory activity in murine ischemia-reperfusion injury. Gastroenterology (2001) 120:460–469.
   PubMed Web of Science ®Google Scholar
• SUGAWARA K, STEVENS BK, SHASHKIN P et al.: PPARgamma: a candidate gene for ileitis in the SAMP1/ YitFc mice model of Crohn's disease. Proceedings of the Digestive Disease Week, Orlando, USA (2003):A368.
   Google Scholar
• GHANIM H, GARG R, ALJADA A et al.:Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. Clin. Endocrinol Metab. (2001) 86:1306–1312.
   Google Scholar
• KATSUKI A, SUMIDA Y, MURATA K et al.: Troglitazone reduces plasma levels of tumor necrosis factor-alpha in obese patients with Type 2 diabetes. Diabetes Obesity Metab. (2000) 2:189–191.
   PubMed Web of Science ®Google Scholar
• HAFFNER SM, GREENBERG AS, WESTON WM, CHEN H, WILLIAMS K, FREED MI: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with Type 2 diabetes mellitus. Circulation (2002) 106:679-684. ao.MARX N, FROEHLICH J, SIAM L et al.: Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in Type 2 diabetic patients with coronary artery disease. Arteriosclec Thromb. Vasc. Biol. (2003) 23:283–288.
   Google Scholar
• SU C, LEWIS JD, DEREN J et al: Peroxisome proliferators-activated receptor ligand rosiglitazone for the treatment of active Crohn's disease. Proceedings of the Digestive Disease Week, Orlando, USA (2003):A380.
   Google Scholar
• SLONIM AE, BULONE L, DAMORE MB et al: A preliminary study of growth hormone therapy for Crohn's disease. New Engl. I Med. (2000) 342:1633–1637.
   PubMed Web of Science ®Google Scholar
• HIATT RB, GOODMAN I: Long term results in the treatment of regional ileitis with coherin. Amj Gastroenterol (1977) 67(3):274–277.
   PubMed Web of Science ®Google Scholar
• LICHTENSTEIN GR, JACOBY HI: Coherin peptides induce clinical response and remission in patients with active Crohn's disease. Proceedings of the American College of Gastroenterology Annual Meeting, Seattle, USA (2002):A763.
   Google Scholar
• LICHTENSTEIN GR, JACOBY HI: Coherin peptides effectively maintain remission in patients with Crohn's disease for 2 years. Proceedings of the American College of Gastroenterology Annual Meeting, Seattle, USA (2002):A764.
   Google Scholar
• •The re-use of coherin, a peptide extract of bovine and porcine posterior pituitary gland that had been used several years ago, has stimulated interest in this agent as an alternative treatment for CD.
   Google Scholar
• ARONCHICK C, DALKE D, IONNA S, RIFF D, SCHIFF M: Medroxyprogesterone acetate is effective in the treatment of ulcerative colitis. Proceedings of the Digestive Disease Week, Atlanta, USA (2001):A455.
   Google Scholar
• SCHREIBER AD, INDIK ZK, ROSE M: Medroxyprogesterone acetate, a progestin and partial glucocorticoid agonist/ antagonist with anti-inflammatory activity in IBD, does not suppress the level of circulating lymphocytes. Proceedings of the American College of Gastroenterology Annual Meeting, Baltimore, USA (2003):A527.
   Google Scholar
• ANDUS T, KLEBL G, ROGLER G, BREGENZER N, SCHOLMERICH J, STRAUB RH: Patients with refractory Crohn's disease or ulcerative colitis respond to dehydroepiandrosterone: a pilot study. Aliment. Pharmacol Ther. (2003) 17:409–414.
   PubMed Web of Science ®Google Scholar
• •The first pilot study of the use of DHEA in CD based on the fact that some CD patients have decreased levels of DHEAS and that DHEA inhibits the activation of NF-x13.
   Google Scholar
• CHIKANO S, SAWADA K, SHIMOYAMA T et al.: IL-18 and IL-12 induce inflammation and fatty liver in mice in an interferon gamma dependent manner. Gut (2000) 47:779–786.
   PubMed Web of Science ®Google Scholar
• SIEGMUND B, RIEDER F, ALBRICH S et al.: Adenosine kinase inhibitor GP515 improves experimental colitis in mice. Pharmacol Exp. Then (2001) 296(1):99–105.
   PubMed Web of Science ®Google Scholar
• RUTGEERTS P, REINISCH W, COLOMBEL JF et al.: Preliminary results of a Phase I/II study of Huzaf, an anti-interferon gamma monoclonal antibody, in patients with moderate to severe active Crohn's disease. Proceedings of the Digestive Disease Week, San Francisco, USA (2002):A505.
   Google Scholar
• •A different approach to treatment of CD as IFN-y is thought to be a key cytokine that enhances the development of a TH1 irmrtune response and also suppresses the proliferation of TH2 cells.
   Google Scholar
• DUBINSKY MC, HASSARD PV, SEIDMAN EG et al: An open label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy. Inflamm. Bowel Dis. (2001) 7:181–189.
   PubMed Web of Science ®Google Scholar
• DUBINSKY MC, FELDMAN EJ, ABREU MT, TARGAN SR, VASILIAUSKAS EA: Thioguanine (6-TG): a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine. Am. J. Gastroenterol (2003) 98:1058–1063.
   PubMed Web of Science ®Google Scholar
• HERRLINGER KR, KREISEL W, SCHWAB M et al.: Open prospective trial on 6-thioguanine for chronic active Crohn's disease. Proceedings of the Digestive Disease Week, San Francisco, CA, USA (2002):A432.
   Google Scholar
• STORK LC, ERDMARU G, ADAMSON P et al.: Oral 6-thioguanine (TG) causes relatively mild and reversible hepatic veno-occlusive disease (VOD). Proceedings of the Annual Meeting of the Hematology Oncology (Huntingt) Society (1998):A672.
   Google Scholar
• DUBINSKY MC, VASILIAUSKAS EA, SINGH H et al.: 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology (2003) 125:298–303.
   PubMed Web of Science ®Google Scholar
• •Raises awareness of NRH as a side effect of using 6-TG to treat IBD patients.
   Google Scholar
• PRAJAPATI DN, KNOX JF, EMMONS J, SAEIAN K, CSUKA ME, BINION DG: Leflunomide treatment of Crohn's disease patients intolerant to standard immunomodulator therapy. J. Clio. Gastroenterol (2003) 37(2):125–128.
   PubMed Web of Science ®Google Scholar
• •Use of an irnmunomodulator not previously used to treat IBD helps with expanding the therapeutic armarnentariurn. oa. SANDBORN WJ, PRESENT DH, ISAACS KL et al.: Tacrolimus for the treatment of fistulas in patients with Crohn's disease: A randomized, placebo-controlled trial. Gastroenterology (2003) 125:380–388.
   Google Scholar
• RUTGEERTS P, VAN ASSCHE G, D'HAENS G et al.: Ornidazole for prophylaxis of postoperative Crohn's disease: Final results of a double blind placebo controlled trial. Proceedings of the Digestive Disease Week, San Francisco, CA, USA. (2002):A80.
   Google Scholar
• ••First report of a potentially useful agent toprevent or delay post-operative recurrence of CD, but patient noncompliance may be an issue secondary to drug side effects.
   Google Scholar
• SHAFRAN I, JOHNSON LK, HAMM L, MURDOCK RH: Efficacy and tolerability of rifaximin, a non-absorbed oral antibiotic in the treatment of active Crohn's disease: Results of an open-label study. Proceedings of the American College of Gastroenterology Annual Meeting, Baltimore, USA (2003):A281.
   Google Scholar
• •A non-absorbable oral antibiotic that appears to be of benefit in CD though a randomised, double-blind, placebo-controlled trial is awaited for confirmation of this benefit and lack of side effects.
   Google Scholar
• STALLMACH A, WITTIG BM, MOSER C et al.: Safety and efficacy of intravenous pulse cyclophosphamide in acute steroid refractory inflammatory bowel disease. Gut (2003) 52:377–382.
   PubMed Web of Science ®Google Scholar
• •Preliminary data on a chemotherapeutic agent that may prove to be useful in CD patients.
   Google Scholar
• Expert Op/n. Investig. Drugs (2004) 13(4)
   Google Scholar
• REINISCH W, NAHAVANDI H, SANTELLA R et al.: Extracorporeal photochemotherapy in patients with steroid-dependent Crohn's disease: a prospective pilot study. Aliment. Pharmacol. Ther. (2001) 15:1313–1322.
   PubMed Web of Science ®Google Scholar
• DITSCHKOWSKI M, EINSELE H, SCHWERDTFEGER R et al: Improvement of inflammatory bowel disease after allogeneic stem-cell transplantation. Transplantation (2003) 75(10):1745–1747.
   PubMed Web of Science ®Google Scholar
• SUMMERS RW, ELLIOTT DE, QADIR K et al.: Triclomis suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease. Am. Gastiventerol (2003) 98:2034–2041.
   PubMed Web of Science ®Google Scholar
• •Preliminary data on the use of non-disease-producing intestinal helminthes to induce a TH2 response and downregulate a chronic TH1 response, which is thought to be one of the pathogenesic mechanisms of CD.
   Google Scholar